GPEdit

GPEdit maps adenosine-to-inosine (A-to-I) RNA editing events and their genetic and pharmacogenomic associations across 33 human cancer types using data from over 10,000 cancer samples.

Key Features:

• Extensive edQTL analysis: Performs RNA editing quantitative trait loci (edQTL) mapping across 33 human cancer types using data from over 10,000 cancer samples and identifies 320,029 edQTLs.
• Clinical associations: Links edQTLs to patient outcomes and genetic risk loci, reporting 1,688 edQTLs associated with overall survival and 4,672 edQTLs connected to GWAS risk loci.
• Pharmacogenomic associations: Identifies associations between RNA editing events and response to over 1,000 anti-cancer drugs, with approximately 3.5 million significant associations.

Scientific Applications:

• Cancer progression mechanisms: Uses RNA editing and edQTL data to investigate molecular mechanisms underlying cancer progression.
• Therapy resistance and pharmacogenomics: Relates RNA editing and genetic variants to drug response profiles to study mechanisms of therapy resistance.
• Biomarker discovery and precision oncology: Supports identification of RNA-editing-related biomarkers and integration with clinical outcomes to inform targeted and personalized treatments.

Methodology:

Systematic edQTL analysis across diverse cancer types using extensive datasets to map genetic variants associated with RNA editing events and correlating these findings with patient survival data and drug response profiles.